17 completed, 1 active not recruiting, 1 unknown. 6 Phase 3, 5 Phase 4, 4 Phase 2, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Active not recruiting 1 |
| Phase 4 | 5 | Completed 4, Unknown 1 |
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Completed 1 |
Follow FluBlok: new trials by email Literature Review of FluBlok trials Research Report on FluBlok
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo - Pneumococcal Disease | Phase 3 | Active not recruiting | Vaxcyte, Inc. | 1390 | 2026-01-12 | 2026-11-02 |
| Immunogenicity of Influenza Vaccinations Flucelvax® (ccIIV3), Flublok® (RIV3) - Influenza | Phase 4 | Completed | Duke University | 606 | 2024-09-09 | 2026-07-28 |
| Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures FluBlok, Placebo - Influenza, Human | Phase 4 | Completed | The University of Hong Kong | 977 | 2020-10-05 | 2026-05-15 |
| Recombinant Influenza Vaccination in U.S. Nursing Homes Recombinant Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine - Influenza, Influenza -Like Illness | Phase 4 | Unknown | Insight Therapeutics, LLC | 1989 | 2019-07-20 | 2023-03-15 |
| Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP Flublok, Flucelvax, Fluarix - Influenza | Phase 4 | Completed | Centers for Disease Control and Prevention | 944 | 2018-09-12 | 2024-07-22 |
| Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers Trivalent Influenza Vaccine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Early Phase 1 | Completed | Roswell Park Cancer Institute | 130 | 2017-10-17 | 2023-06-06 |
| Open-Label Influenza Vaccine Evaluation High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine - Immune Response | Not applicable | Completed | Marshfield Clinic Research Foundation | 179 | 2016-09-01 | 2025-12-10 |
| Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors Hepatitis A Vaccine, Laboratory Biomarker Analysis, Tetanus Toxoid Vaccine - Astrocytoma, Glioma | Completed | Wake Forest University Health Sciences | 55 | 2016-05-01 | 2021-10-29 | |
| PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine - Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 1 | Completed | Donald T. Weed, MD, FACS | 16 | 2016-04-25 | 2021-06-15 |
| Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults Recombinant Influenza Vaccine, Inactivated Influenza Vaccine - Human Influenza | Completed | Protein Sciences Corporation | 254648 | 2015-11-01 | 2017-10-12 | |
| Comparison of Three Licensed Influenza Vaccines FluBlok, Fluzone, FluCelVax - Influenza | Phase 4 | Completed | University of Rochester | 413 | 2015-10-28 | 2021-11-30 |
| Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age Flublok, Afluria - Influenza | Phase 3 | Completed | Protein Sciences Corporation | 2640 | 2013-03-01 | 2015-02-18 |
| Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults Recombinant Influenza HA Vaccine (H5N1) - Influenza | Phase 2 | Completed | UMN Pharma Inc. | 87 | 2010-10-01 | 2011-02-08 |
| Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults UMN-0501 - Influenza, Virus Diseases | Phase 2 | Completed | UMN Pharma Inc. | 90 | 2009-10-01 | 2010-02-08 |
| Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok FluBlok®, Placebo - Influenza | Phase 3 | Completed | Sanofi | 4648 | 2007-09-15 | 2022-04-06 |
| Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV FluBlok Influenza Vaccination, TIV (Fluzone) Influenza Vaccination - Influenza | Phase 3 | Completed | Protein Sciences Corporation | 602 | 2007-09-01 | 2011-07-27 |
| Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics Influenza Vaccination - Influenza | Phase 1 / Phase 2 | Completed | Protein Sciences Corporation | 156 | 2006-10-01 | 2009-12-17 |
| Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults Influenza Vaccination - Influenza | Phase 3 | Completed | Protein Sciences Corporation | 870 | 2006-10-01 | 2009-12-17 |
| Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults Influenza Vaccine, recombinant Hemagglutinin - Influenza | Phase 2 / Phase 3 | Completed | Protein Sciences Corporation | 459 | 2004-11-01 | 2010-01-12 |
Influenza, Human (15) · Astrocytoma (1) · Glioma (1) · Head and Neck Neoplasms (1) · Influenza in Birds (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Oligodendroglioma (1) · Pneumococcal Infections (1) · Pneumonia (1) · Squamous Cell Carcinoma of Head and Neck (1) · Virus Diseases (1)
Protein Sciences Corporation (6) · UMN Pharma Inc. (2) · Centers for Disease Control and Prevention (1) · Donald T. Weed, MD, FACS (1) · Duke University (1) · Insight Therapeutics, LLC (1) · Marshfield Clinic Research Foundation (1) · Roswell Park Cancer Institute (1) · Sanofi (1) · The University of Hong Kong (1) · University of Rochester (1) · Vaxcyte, Inc. (1) · Wake Forest University Health Sciences (1)
United States (16) · Japan (2) · Hong Kong (1)
Alan C. Wine, MD (1) · Angela Branche, MD (1) · Bob Weiss, MD (1) · Brandon Essink, MD (1) · Brendan Flannery, PhD (1) · Darrell Herrington, DO (1) · Donald T Weed, MD, FACS (1) · Elizabeth A Griffiths (1) · Emmanuel B Walter, MD, MPH (1) · Eric Sheldon (1) · Fatimah Dawood, MD (1) · Frank Eder, MD (1) · George Bauer, MD (1) · Gregory A. Poland, MD (1)
PMID 26787832, PMID 28325769, PMID 17426277, PMID 19716456, PMID 19879222, PMID 21277410, PMID 26529070, PMID 31214178, PMID 31598646, PMID 34245243, PMID 34774360, PMID 36031405, PMID 38177116, PMID 39041887, PMID 39745702, PMID 42856744
272201400005C-P00019-9999-4 (1), P30CA012197 (1), U01AI153700 (1)